FDA Continues To Speed PD-1/L1 Drugs To Market

The four-month review of Merck’s Keytruda for first-line lung cancer is a reminder of how quickly the agency has acted on the immune checkpoint inhibitors.

The approval of the first-line lung cancer indication for Merck & Co. Inc.’s PD-1 inhibitor Keytruda in just four months – two months before the user fee goal date – shows that FDA’s Office of Hematology and Oncology Products is still willing and able to meet its unofficial internal deadline for early action for major approvals.

With some of the most significant product reviews across the agency under its purview, OHOP set up its own internal...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approvals

More from Product Reviews

  • data

    New EU Filings

     
    • By 

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By 

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>